Nurix Therapeutics公布的最新1a期临床试验数据显示，其研究性疗法在重度预处理的复发或难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者群体中，展现出令人鼓舞的疗效。该患者群体既往接受过多线治疗，临床需求高度未满足。关键疗效指标显示，患者的中位无进展生存期达到了22.1个月，总缓解率高达83%。这些积极数据为后续临床开发提供了有力支持，并凸显了该疗法在治疗这一难治性血液恶性肿瘤方面的潜力。
Nurix Therapeutics公布的最新1a期临床试验数据显示，其研究性疗法在重度预处理的复发或难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者群体中，展现出令人鼓舞的疗效。该患者群体既往接受过多线治疗，临床需求高度未满足。关键疗效指标显示，患者的中位无进展生存期达到了22.1个月，总缓解率高达83%。这些积极数据为后续临床开发提供了有力支持，并凸显了该疗法在治疗这一难治性血液恶性肿瘤方面的潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.